Nature Immunology, Published online: 24 July 2025; doi:10.1038/s41590-025-02233-4

Here the authors identify the granin hormone SCG2 as a ligand for the inhibitory receptor LILRB4. They show that SCG2 released from tumors can suppress antitumor immune responses via this interaction, indicating possible therapeutic strategies.



Summary

A study published in Nature Immunology identifies the granin hormone SCG2 as a ligand for the inhibitory immune receptor LILRB4. Researchers found that tumors release SCG2, which then binds to LILRB4 on immune cells. This interaction triggers suppression of antitumor immune responses, effectively shielding the tumor from immune attack. The discovery highlights a novel mechanism by which tumors evade the immune system and suggests potential therapeutic strategies targeting the SCG2-LILRB4 pathway to enhance antitumor immunity.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!